Bill > S2336

This bill aims to broaden the references to opioid overdose reversal drugs in certain Department of Health and Human Services (HHS) grant programs, ensuring that such references are not limited to only naloxone. Specifically, the bill requires the HHS Secretary to update regulations and guidance for grant programs addressing opioid misuse to include any FDA-approved opioid overdose reversal drug, not just naloxone. Within one year of the bill's enactment, the Secretary must update existing references in two key grant programs: the State and Tribal Opioid Response Grants and the grant program for priority substance use disorder prevention needs. The bill recognizes that there may be multiple effective medications for reversing opioid overdoses beyond naloxone and seeks to ensure that grant programs remain flexible and open to emerging treatment options. By doing so, the legislation aims to support a more comprehensive approach to addressing the opioid epidemic and potentially save more lives by allowing for a broader range of approved overdose reversal treatments.

Health and Social Services

https://www.congress.gov/bill/119th-congress/senate-bill/2336/all-info